Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/234387IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/EP2020/064132 Applicant CYTUNE PHARMA Inventor MOEBIUS, Ulrich
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βɣ (IL-2/IL-15Rβɣ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβɣ agonists on 2, 3 or 4 consecutive days followed by days without administration.
2.WO/2020/235947CACB1-DERIVED PEPTIDE, VARIANT OF CACB1-DERIVED PEPTIDE, AND USE THEREOF
WO 26.11.2020
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No PCT/KR2020/006650 Applicant KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor YOUN, Dong-ho
The present invention relates to a Cacb1-derived peptide, a variant of the Cacb1-derived peptide, a composition for the prevention or treatment of hypertension, and a composition for the relaxation of blood vessels, the compositions comprising same. The Cacb1-derived peptide and the variant of the Cacb1-derived peptide according to the present invention have an excellent blood pressure-lowering effect and fewer side effects, and are easy to manufacture and industrialize, and thus can be effectively used in the development of a novel therapeutic agent for hypertension. In addition, the peptide and the variant thereof have a potential vasodilating effect, and thus are expected to be used as candidate materials for a therapeutic agent for diseases that can be treated or ameliorated by vasodilation, such as angina, prostatic hyperplasia, and erectile dysfunction.
3.WO/2020/233176GROWTH FACTOR SUSTAINED RELEASE MICROSPHERE, TISSUE ENGINEERING CARTILAGE COMPOSITE STENT AND MANUFACTURE METHOD THEREFOR
WO 26.11.2020
Int.Class A61K 9/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
Appl.No PCT/CN2020/075159 Applicant CHINESE PLA GENERAL HOSPITAL Inventor GUO, Quanyi
Disclosed are a growth factor sustained release microsphere, a tissue engineering cartilage composite stent and a manufacture method therefor. The growth factor sustained release microsphere comprises a polylactic acid-glycolic acid copolymer host material and a recombinant human transforming growth factor β3 encapsulated in the host material, wherein the encapsulation amount of the recombinant human transforming growth factor β3 in the microsphere is 5ng/mg~200ng/mg; the sustained release period of the microsphere is 28 days or more.
4.WO/2020/236146A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME
WO 26.11.2020
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2019/033046 Applicant THE TEXAS A&M UNIVERSITY SYSTEM Inventor LIU, Wenshe
Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids include phage coat protein genes with a combinatorial region that encodes at least one cysteine and at least one non-canonical amino acid. The transformation results in the production of phage particles with phage coat proteins where the cysteine and the non-canonical amino acid couple to one another to form a cyclic peptide library. Phage particles are then screened against the desired target to select bound cyclic peptides. Amino acid sequences of the selected cyclic peptides are then identified. Additional embodiments pertain to methods of constructing a phage display library that encodes the cyclic peptides. Further embodiments of the present disclosure pertain to the produced cyclic peptides, phage display libraries and phage particles.
5.WO/2020/234195HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE
WO 26.11.2020
Int.Class A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
Appl.No PCT/EP2020/063732 Applicant UNIVERSITAET ZUERICH Inventor HUGELSHOFER, Michael
The present invention relates generally to methods for treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF) comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp, or the functional analogue thereof, to form a complex with, and thereby neutralise, the cell-free Hb. Aspects of the invention further relate to compositions and kits of an artificial CSF comprising Hp.
6.WO/2020/236615MPS MODIFIED PEPTIDES AND USE THEREOF
WO 26.11.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2020/033188 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor WU, Reen
This disclosure provides an isolated polypeptide therapeutics, polynucleotides encoding the polypeptides and antibodies that bind to the polypeptides are also provided. Therapeutic and diagnostic uses are further provided.
7.WO/2020/236655IL-7-FC-FUSI0N PROTEINS
WO 26.11.2020
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2020/033276 Applicant XENCOR, INC. Inventor BERNETT, Matthew
Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
8.WO/2020/236815MINIGENE THERAPY
WO 26.11.2020
Int.Class A61K 31/711
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Appl.No PCT/US2020/033600 Applicant UNIVERSITY OF MASSACHUSETTS Inventor GAO, Guangping
Aspects of the disclosure relate to compositions and methods useful for treating ocular ciliopathies, for example Leber congenital amaurosis (LCA). In some embodiments, the disclosure provides isolated nucleic acids comprising a transgene encoding a CEP290 protein fragment, and methods of treating ocular ciliopathies using the same.
9.WO/2020/234384CYCLODEXTRIN BASED INJECTABLE COFORMULATIONS OF SGLT2 INHIBITORS AND INCRETIN PEPTIDES
WO 26.11.2020
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
Appl.No PCT/EP2020/064128 Applicant MEDIMMUNE LIMITED Inventor LAINE, Anne-Laure
Provided herein are coformulations comprising cyclodextrin that allow for concurrent, subcutaneous administration of sodium glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, and incretin peptides, such as GLP-1/Glucagon dual agonist peptides.
10.WO/2020/236964ENGINEERED EXPRESSION OF CELL SURFACE AND SECRETED SIALIDASE BY CAR T CELLS FOR INCREASED EFFICACY IN SOLID TUMORS
WO 26.11.2020
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2020/033852 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor POSEY, Avery D.
The present disclosure provides modified immune cells or precursors thereof (e.g. modified T cells) comprising a chimeric cell surface sialidase or a variant sialidase precursor protein. Compositions and methods of treatment are also provided.